Lubricity additives for hydrocarbon fuels are provided according to formula I: ##STR00001##
wherein n is 1 or 0; each Q is independently selected from oxygen and sulfur; each R is independently selected from C8-C60 alkenyl groups which are substituted or unsubstituted; and L is a linking group comprising 0-20 carbons which may be substituted or unsubstituted and may optionally comprise catenary heteroatoms. Fuel mixtures comprising a hydrocarbon fuel; and a lubricity additive according to the present disclosure are also provided. Methods of making lubricity additives comprise reacting an alkenyl succinic anhydrides (ASA's) with certain bisamides or bisthioamides.

Lubricity additives for hydrocarbon fuels are provided according to formula I: ##STR00001##
wherein n is 1 or 0; each Q is independently selected from oxygen and sulfur; each R is independently selected from C8-C60 alkenyl groups which are substituted or unsubstituted; and L is a linking group comprising 0-20 carbons which may be substituted or unsubstituted and may optionally comprise catenary heteroatoms. Fuel mixtures comprising a hydrocarbon fuel; and a lubricity additive according to the present disclosure are also provided. Methods of making lubricity additives comprise reacting an alkenyl succinic anhydrides (ASA's) with certain bisamides or bisthioamides.

The present invention provides a polymer composition comprising a polymer and an antioxidant comprising a diarylamine-based compound represented by General Formula (1): ##STR00001##
where, in General Formula (1), A.sup.1 and A.sup.2 each independently represent a C.sub.6 to C.sub.18 arylene group which may have a substituent, and A.sup.3 and A.sup.4 each independently represent an organic group having a cyclic imide structure which may have a substituent.

This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.

This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.

The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.

The present invention provides novel antifibrinilytic compounds, processes for their preparation, pharmaceutical and veterinary compositions thereof, and their use in medicine, in particular for the treatment of bleeding.

The present invention provides novel antifibrinilytic compounds, processes for their preparation, pharmaceutical and veterinary compositions thereof, and their use in medicine, in particular for the treatment of bleeding.

The present invention relates to an alkyd resin composition comprising a. 1-60 wt % of an imide compound according to anyone of formulas Ia, Ib, Ic, Id or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; R2 and R5 are independently H, or a C1-C20 hydrocarbon group; R3 and R4 are independently H, or a C1-C20 hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl; b. 10-40 wt % of an alcohol having a number average hydroxy functionality ≧2.0; c. 30-70 wt % of fatty acids or vegetable oils; d. 0-50 wt % of a mono and/or polyfunctional compound capable of esterification, which compound is different from the compounds used in a, b and c; wherein the wt % is determined relative to the total of weight of compounds a, b, c and d.

##STR00001##

Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.